Skip to search formSkip to main contentSkip to account menu

osimertinib

Known as: Mereletinib, N-(2-{[2-(dimethylamino)ethyl](methyl)amino}-4-methoxy-5-{[4-(1-methyl-1H-indol-3-yl)pyrimidin-2-yl]amino}phenyl)prop-2-enamide 
A third-generation, orally available, irreversible, mutant-selective, epidermal growth factor receptor (EGFR) inhibitor, with potential… 
National Institutes of Health

Related topics

Related topics

11 relations

Narrower (3)

AZD9291Tagrissoosimertinib mesylate

Broader (3)

Antineoplastic AgentsPiperazinesProtein Kinase Inhibitors
Breast Cancer Resistance Protein Inhibitors [MoA]Kinase Inhibitors [MoA]NCIt Antineoplastic Agent TerminologyReceptor Tyrosine Kinase Inhibition

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2020
2020
Osimertinib in non-small cell lung cancer (NSCLC) with atypical EGFR activating mutations: A retrospective multicenter study.
9570 Background: Osimertinib (osi) is a 3rd generation EGFR tyrosine kinase inhibitor (TKI) approved for first line (1L… 
2020
2020
Plasma screening for the T790M mutation of EGFR and phase 2 study of osimertinib efficacy in plasma T790M–positive non–small cell lung cancer: West Japan Oncology Group 8815L/LPS study
Liquid biopsy allows the identification of patients whose tumors harbor specific mutations in a minimally invasive manner. No… 
2018
2018
Phase II trial of gefitinib plus pemetrexed after relapse using first-line gefitinib in patients with non-small cell lung cancer harboring EGFR gene mutations.
Review
2018
Review
2018
Resistance to epidermal growth factor receptor tyrosine kinase inhibitors, T790M, and clinical trials.
Tumours with sensitizing mutations in the EGFR gene constitute a distinct molecular subgroup of non-small-cell lung cancers… 
2018
2018
An Accurate and Effective Method for Measuring Osimertinib by UPLC-TOF-MS and Its Pharmacokinetic Study in Rats
Osimertinib, a new-generation inhibitor of the epidermal growth factor, has been used for the clinical treatment of advanced… 
2018
2018
Efficacy and safety results of ramucirumab in combination with osimertinib in advanced T790M-positive EGFR-mutant NSCLC.
9053Background: Progression of EGFR-mutant non-small cell lung cancer (NSCLC) occurs in most patients (pts) despite initial… 
2017
2017
The activation of SRC family kinases and focal adhesion kinase with the loss of the amplified, mutated EGFR gene contributes to the resistance to afatinib, erlotinib and osimertinib in human lung…
Second- and third-generation inhibitors of epidermal growth factor receptor (EGFR) tyrosine kinase activity (EGFR-TKIs) are… 
2017
2017
Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series
Review
2017
Review
2017
Epidermal Growth Factor Receptor Mutated Advanced Non-Small Cell Lung Cancer: A Changing Treatment Paradigm.
2016
2016
Follow up analysis by exosomal miRNAs in EGFR mutated non-small cell lung cancer (NSCLC) patients during osimertinib (AZD9291) treatment: A potential prognostic biomarker tool.
e23035Background: NSCLC patients harboring EGFR mutations are able to receive approved tyrosine kinase inhibitors (TKIs) but to… 
By clicking accept or continuing to use the site, you agree to the terms outlined in our Privacy Policy (opens in a new tab), Terms of Service (opens in a new tab), and Dataset License (opens in a new tab)